The investigational drug arbaclofen makes autistic people’s brains respond to a visual task more like non-autistic people’s brains do.

Motor differences are more relevant than has historically been appreciated for understanding, assessing and supporting people on the spectrum.

Developmental delay, intellectual disability and behavioral issues are common among people who have mutations in MYT1L, a gene with strong ties to autism.

How chemical tags called methyl groups position themselves on genetic sequences may hint at some of the causes of autism.

In this edition of Null and Noteworthy, the Interagency Autism Coordinating Committee grapples with “groundbreaking” research and two reviews of interventions come to conflicting conclusions.

Shafali Jeste has spent the bulk of her scientific career searching for biological markers of autism. Her goal: to improve lives through early diagnosis and speedy testing of therapies.

A potential new gene therapy delivered via a single injection mimics ratios of proteins normally found in cells.

Andrew Whitehouse talks about his conservation efforts in the Australian Outback, what it’s like to be an identical twin and why he leaves work promptly at 5 p.m.

People with autism have more mutations than others do in both mitochondrial DNA and nuclear DNA that affects mitochondrial function.

Many autistic children rate the therapy as less effective at treating their anxiety than their parents and clinicians do.